As all these three tested lines had disruptive mutations in TP53 (as determined by Poeta et al [15], data not shown), we also tested the KD effects on two p53 wild type OSCC cell lines derived from a primary OSCC (UM-SCC-17A) and from a metastatic disease (UM-SCC-47), respectively [14]. This evidence concerns the gene TP53 and metastatic neoplasm.